Home › Compare › LCKYF vs ABBV
LCKYF yields 984.74% · ABBV yields 3.06%● Live data
📍 LCKYF pulled ahead of the other in Year 1
Combined, LCKYF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LCKYF + ABBV for your $10,000?
Golden Sky Minerals Corp. operates as a mineral exploration company in Canada. The company engages in acquisition, development, exploration, and evaluation of mineral properties. It primarily explores for gold deposits. The company holds 100% interest in the Lucky Strike property located in Yukon, Canada; the BRC property located in Yukon, Canada; and the Gold Source property located in southwest of Dawson, Yukon. It also holds 100% interest in the Hot Spot Property located in south of Dawson, Yukon; the King's Ransom Property; the Bull's Eye Property located in south of Dawson, Yukon; the Rayfield Property located in British Columbia, Canada; and the Eagle Mountain gold property that covers an area of approximately 10,000 hectares located in the Cassiar District of British Columbia. The company was formerly known as Luckystrike Resources Ltd. and changed its name to Golden Sky Minerals Corp. in February 2020. Golden Sky Minerals Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.
Full LCKYF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.